The Effect of Tacrolimus in patients with recurrent implantation failure
- Conditions
- Recurrent Implantation Failure.Female infertility of uterinN-97.2
- Registration Number
- IRCT20171007036623N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 10
History of 3 or more failed IVF/ET cycles with morphologically and developmentally average to good-quality embryo( 7 or more blastomeres and less than 10% fragmentation in day 3 ) into an adequately prepared endometrium (endometrial thickness equal or more than 8 mm); Women who had regular menses (25 to 35 days); Women who had normal karyotype;
women who had at least one of these Immunological disorders in their peripheral blood sample between day of 5 to 10 of menstrual cycle: IFN-g/IL-4 equal or more than 10.3 or Nk-cell percentage greater than 12%
Present of sub mucosal fibroids, endometrial polyps, intrauterine adhesions, congenital anomalies of uterus or hydrosalpinges
History of active autoimmune disease (With assessment of ANA, Anti-TG, Anti-TPO, Anti-dsDNA); Women with acquired or inherited thrombophilia (With assessment of Factor2, Factor5, Factor 8, Fibrinogen, Anti- Cardiolipin, Anti-Phospholipid Antibody, Lupus Anti-Coagulate, s-MTHFR gene)
Pregnant women; History of miscarriage in a former IVF/ET cycle; Women who received vaccine in the last three months; Women who received steroid hormones in the last 2 months; Women receiving immunotherapy; Women with chronic inflammatory diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expression of P53 gene. Timepoint: Measure twice: before and after treatment. Method of measurement: qRT-PCR.;Expression of LIF gene. Timepoint: Measure twice: before and after treatment. Method of measurement: qRT-PCR.;Expression of IL-10 gene. Timepoint: Measure Twice: before and after treatment. Method of measurement: qRT-PCR.;Expression of IL-17 gene. Timepoint: Measure twice: before and after treatment. Method of measurement: qRT-PCR.
- Secondary Outcome Measures
Name Time Method